Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Galectin-13/placental protein 13: redox-active disulfides as switches for regulating structure, function and cellular distribution.

Yang T, Yao Y, Wang X, Li Y, Si Y, Li X, Ayala GJ, Wang Y, Mayo KH, Tai G, Zhou Y, Su J.

Glycobiology. 2019 Oct 4. pii: cwz081. doi: 10.1093/glycob/cwz081. [Epub ahead of print]

PMID:
31584064
2.

A new regulatory mechanism for Raf kinase activation, retinoic acid-bound Crabp1.

Wook Park S, Nhieu J, Persaud SD, Miller MC, Xia Y, Lin YW, Lin YL, Kagechika H, Mayo KH, Wei LN.

Sci Rep. 2019 Jul 29;9(1):10929. doi: 10.1038/s41598-019-47354-7.

3.

Corrigendum to "An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature" [Vaccine 36(21) 3054-3060].

Huijbers EJM, van Beijnum JR, Lê CT, Langman S, Nowak-Sliwinska P, Mayo KH, Griffioen AW.

Vaccine. 2019 Jul 9;37(30):4231-4232. doi: 10.1016/j.vaccine.2019.06.010. Epub 2019 Jun 13. No abstract available.

4.

NMR-based insight into galectin-3 binding to endothelial cell adhesion molecule CD146: Evidence for noncanonical interactions with the lectin's CRD β-sandwich F-face.

Zhang Z, Miller MC, Xu X, Song C, Zhang F, Zheng Y, Zhou Y, Tai G, Mayo KH.

Glycobiology. 2019 Jul 19;29(8):608-618. doi: 10.1093/glycob/cwz036.

PMID:
31094416
5.

Resetting the ligand binding site of placental protein 13/galectin-13 recovers its ability to bind lactose.

Su J, Cui L, Si Y, Song C, Li Y, Yang T, Wang H, Mayo KH, Tai G, Zhou Y.

Biosci Rep. 2018 Dec 14;38(6). pii: BSR20181787. doi: 10.1042/BSR20181787. Print 2018 Dec 21.

6.

Galectin-3 binds selectively to the terminal, non-reducing end of β(1→4)-galactans, with overall affinity increasing with chain length.

Miller MC, Zheng Y, Zhou Y, Tai G, Mayo KH.

Glycobiology. 2019 Jan 1;29(1):74-84. doi: 10.1093/glycob/cwy085.

PMID:
30204870
7.

Preparation of individual galactan oligomers, their prebiotic effects, and use in estimating galactan chain length in pectin-derived polysaccharides.

Zheng Y, Li L, Feng Z, Wang H, Mayo KH, Zhou Y, Tai G.

Carbohydr Polym. 2018 Nov 1;199:526-533. doi: 10.1016/j.carbpol.2018.07.048. Epub 2018 Jul 17.

PMID:
30143159
8.

An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature.

Huijbers EJM, van Beijnum JR, Lê CT, Langman S, Nowak-Sliwinska P, Mayo KH, Griffioen AW.

Vaccine. 2018 May 17;36(21):3054-3060. doi: 10.1016/j.vaccine.2018.03.064. Epub 2018 Apr 11. Erratum in: Vaccine. 2019 Jul 9;37(30):4231-4232.

9.

Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.

Paz H, Joo EJ, Chou CH, Fei F, Mayo KH, Abdel-Azim H, Ghazarian H, Groffen J, Heisterkamp N.

J Exp Clin Cancer Res. 2018 Mar 27;37(1):67. doi: 10.1186/s13046-018-0721-7.

10.

Galectins as Molecular Targets for Therapeutic Intervention.

Dings RPM, Miller MC, Griffin RJ, Mayo KH.

Int J Mol Sci. 2018 Mar 19;19(3). pii: E905. doi: 10.3390/ijms19030905. Review.

11.

Adhesion/growth-regulatory galectins tested in combination: evidence for formation of hybrids as heterodimers.

Miller MC, Ludwig AK, Wichapong K, Kaltner H, Kopitz J, Gabius HJ, Mayo KH.

Biochem J. 2018 Mar 15;475(5):1003-1018. doi: 10.1042/BCJ20170658.

PMID:
29321242
12.

Macromolecular assemblies of complex polysaccharides with galectin-3 and their synergistic effects on function.

Zhang T, Miller MC, Zheng Y, Zhang Z, Xue H, Zhao D, Su J, Mayo KH, Zhou Y, Tai G.

Biochem J. 2017 Nov 9;474(22):3849-3868. doi: 10.1042/BCJ20170143.

PMID:
28986508
13.

Chemokines from a Structural Perspective.

Miller MC, Mayo KH.

Int J Mol Sci. 2017 Oct 2;18(10). pii: E2088. doi: 10.3390/ijms18102088. Review.

14.

Novel polysaccharide binding to the N-terminal tail of galectin-3 is likely modulated by proline isomerization.

Miller MC, Zheng Y, Yan J, Zhou Y, Tai G, Mayo KH.

Glycobiology. 2017 Nov 1;27(11):1038-1051. doi: 10.1093/glycob/cwx071.

15.

Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation.

von Hundelshausen P, Agten SM, Eckardt V, Blanchet X, Schmitt MM, Ippel H, Neideck C, Bidzhekov K, Leberzammer J, Wichapong K, Faussner A, Drechsler M, Grommes J, van Geffen JP, Li H, Ortega-Gomez A, Megens RT, Naumann R, Dijkgraaf I, Nicolaes GA, Döring Y, Soehnlein O, Lutgens E, Heemskerk JW, Koenen RR, Mayo KH, Hackeng TM, Weber C.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaah6650. doi: 10.1126/scitranslmed.aah6650.

PMID:
28381538
16.

Probing Functional Heteromeric Chemokine Protein-Protein Interactions through Conformation-Assisted Oxime Ligation.

Agten SM, Koenen RR, Ippel H, Eckardt V, von Hundelshausen P, Mayo KH, Weber C, Hackeng TM.

Angew Chem Int Ed Engl. 2016 Nov 21;55(48):14963-14966. doi: 10.1002/anie.201607036. Epub 2016 Oct 27.

17.

Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR.

Ippel H, Miller MC, Vértesy S, Zheng Y, Cañada FJ, Suylen D, Umemoto K, Romanò C, Hackeng T, Tai G, Leffler H, Kopitz J, André S, Kübler D, Jiménez-Barbero J, Oscarson S, Gabius HJ, Mayo KH.

Glycobiology. 2016 Aug;26(8):888-903. doi: 10.1093/glycob/cww021. Epub 2016 Feb 23.

18.

Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.

Miller MC, Ippel H, Suylen D, Klyosov AA, Traber PG, Hackeng T, Mayo KH.

Glycobiology. 2016 Jan;26(1):88-99. doi: 10.1093/glycob/cwv073.

19.

Evaluation of 111In-labeled Anginex as Potential SPECT Tracer for Imaging of Tumor Angiogenesis.

Van Mourik TR, Läppchen T, Rossin R, Van Beijnum JR, Macdonald JR, Mayo KH, Griffioen AW, Nicolay K, Grüll H.

Anticancer Res. 2015 Nov;35(11):5945-54.

PMID:
26504018
20.

Structural significance of galectin design: impairment of homodimer stability by linker insertion and partial reversion by ligand presence.

Vértesy S, Michalak M, Miller MC, Schnölzer M, André S, Kopitz J, Mayo KH, Gabius HJ.

Protein Eng Des Sel. 2015 Jul;28(7):199-210. doi: 10.1093/protein/gzv014. Epub 2015 Mar 21.

PMID:
25796447
21.

Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation.

Läppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Grüll H.

Eur J Med Chem. 2015 Jan 7;89:279-95. doi: 10.1016/j.ejmech.2014.10.048. Epub 2014 Oct 18.

PMID:
25462244
22.

Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis.

Rauthu SR, Shiao TC, André S, Miller MC, Madej É, Mayo KH, Gabius HJ, Roy R.

Chembiochem. 2015 Jan 2;16(1):126-39. doi: 10.1002/cbic.201402474. Epub 2014 Nov 18.

PMID:
25407851
23.

(1)H, (13)C, and (15)N backbone and side-chain chemical shift assignments for the 36 proline-containing, full length 29 kDa human chimera-type galectin-3.

Ippel H, Miller MC, Berbís MA, Suylen D, André S, Hackeng TM, Cañada FJ, Weber C, Gabius HJ, Jiménez-Barbero J, Mayo KH.

Biomol NMR Assign. 2015 Apr;9(1):59-63. doi: 10.1007/s12104-014-9545-3. Epub 2014 Feb 7.

24.

Peptides derived from human galectin-3 N-terminal tail interact with its carbohydrate recognition domain in a phosphorylation-dependent manner.

Berbís MÁ, André S, Cañada FJ, Pipkorn R, Ippel H, Mayo KH, Kübler D, Gabius HJ, Jiménez-Barbero J.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):126-31. doi: 10.1016/j.bbrc.2013.11.063. Epub 2013 Nov 22.

25.

Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa.

Dings RP, Haseman JR, Leslie DB, Luong M, Dunn DL, Mayo KH.

Biochim Biophys Acta. 2013 Jun;1830(6):3454-7. doi: 10.1016/j.bbagen.2013.02.002. Epub 2013 Feb 9.

26.

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

Dings RP, Levine JI, Brown SG, Astorgues-Xerri L, MacDonald JR, Hoye TR, Raymond E, Mayo KH.

Invest New Drugs. 2013 Oct;31(5):1142-50. doi: 10.1007/s10637-013-9932-0. Epub 2013 Feb 8.

27.

Lactose binding to human galectin-7 (p53-induced gene 1) induces long-range effects through the protein resulting in increased dimer stability and evidence for positive cooperativity.

Ermakova E, Miller MC, Nesmelova IV, López-Merino L, Berbís MA, Nesmelov Y, Tkachev YV, Lagartera L, Daragan VA, André S, Cañada FJ, Jiménez-Barbero J, Solís D, Gabius HJ, Mayo KH.

Glycobiology. 2013 May;23(5):508-23. doi: 10.1093/glycob/cwt005. Epub 2013 Jan 31.

28.

Protein lysine-Nζ alkylation and O-phosphorylation mediated by DTT-generated reactive oxygen species.

Kumar N, Ippel H, Weber C, Hackeng T, Mayo KH.

Protein Sci. 2013 Mar;22(3):327-46. doi: 10.1002/pro.2214. Epub 2013 Jan 27.

29.

Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH.

J Pharmacol Exp Ther. 2013 Mar;344(3):589-99. doi: 10.1124/jpet.112.199646. Epub 2012 Dec 11.

30.

Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH.

J Med Chem. 2012 Jun 14;55(11):5121-9. doi: 10.1021/jm300014q. Epub 2012 May 30.

31.

Structural features for α-galactomannan binding to galectin-1.

Miller MC, Klyosov AA, Mayo KH.

Glycobiology. 2012 Apr;22(4):543-51. doi: 10.1093/glycob/cwr173. Epub 2011 Dec 7.

32.

Dual-targeting of αvβ3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo.

Kluza E, Jacobs I, Hectors SJ, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K.

J Control Release. 2012 Mar 10;158(2):207-14. doi: 10.1016/j.jconrel.2011.10.032. Epub 2011 Oct 30.

PMID:
22079810
33.

1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 31 kDa human galectin-7 (p53-induced gene 1) homodimer, a pro-apoptotic lectin.

Nesmelova IV, Berbís MÁ, Miller MC, Cañada FJ, André S, Jiménez-Barbero J, Gabius HJ, Mayo KH.

Biomol NMR Assign. 2012 Oct;6(2):127-9. doi: 10.1007/s12104-011-9339-9. Epub 2011 Sep 7.

PMID:
21898049
34.

Structural aspects of binding of α-linked digalactosides to human galectin-1.

Miller MC, Ribeiro JP, Roldós V, Martín-Santamaría S, Cañada FJ, Nesmelova IA, André S, Pang M, Klyosov AA, Baum LG, Jiménez-Barbero J, Gabius HJ, Mayo KH.

Glycobiology. 2011 Dec;21(12):1627-41. doi: 10.1093/glycob/cwr083. Epub 2011 Jun 28.

35.

Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH.

Clin Cancer Res. 2011 May 15;17(10):3134-45. doi: 10.1158/1078-0432.CCR-10-2443. Epub 2011 Jan 20.

36.

Tumour thermotolerance, a physiological phenomenon involving vessel normalisation.

Dings RP, Loren ML, Zhang Y, Mikkelson S, Mayo KH, Corry P, Griffin RJ.

Int J Hyperthermia. 2011;27(1):42-52. doi: 10.3109/02656736.2010.510495. Epub 2011 Jan 4.

37.

Lactose binding to galectin-1 modulates structural dynamics, increases conformational entropy, and occurs with apparent negative cooperativity.

Nesmelova IV, Ermakova E, Daragan VA, Pang M, Menéndez M, Lagartera L, Solís D, Baum LG, Mayo KH.

J Mol Biol. 2010 Apr 16;397(5):1209-30. doi: 10.1016/j.jmb.2010.02.033. Epub 2010 Feb 23.

PMID:
20184898
38.

Inhibiting tumor growth by targeting tumor vasculature with galectin-1 antagonist anginex conjugated to the cytotoxic acylfulvene, 6-hydroxylpropylacylfulvene.

Dings RP, Van Laar ES, Loren M, Webber J, Zhang Y, Waters SJ, Macdonald JR, Mayo KH.

Bioconjug Chem. 2010 Jan;21(1):20-7. doi: 10.1021/bc900287y.

PMID:
20020769
39.

Synergistic targeting of alphavbeta3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis.

Kluza E, van der Schaft DW, Hautvast PA, Mulder WJ, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K.

Nano Lett. 2010 Jan;10(1):52-8. doi: 10.1021/nl902659g.

PMID:
19968235
40.

p16(INK4a) Peptide mimetics identified via virtual screening.

Klein MA, Mayo KH, Kratzke RA.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):403-5. doi: 10.1016/j.bmcl.2009.10.046. Epub 2009 Oct 15.

PMID:
19914831
41.

NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents.

Tabruyn SP, Mémet S, Avé P, Verhaeghe C, Mayo KH, Struman I, Martial JA, Griffioen AW.

Mol Cancer Ther. 2009 Sep;8(9):2645-54. doi: 10.1158/1535-7163.MCT-09-0383. Epub 2009 Aug 25.

42.

1H, 13C, and 15N backbone and side-chain chemical shift assignments for the 29 kDa human galectin-1 protein dimer.

Nesmelova IV, Pang M, Baum LG, Mayo KH.

Biomol NMR Assign. 2008 Dec;2(2):203-5. doi: 10.1007/s12104-008-9121-9. Epub 2008 Sep 27.

PMID:
19636905
43.

The alpha-galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain.

Miller MC, Klyosov A, Mayo KH.

Glycobiology. 2009 Sep;19(9):1034-45. doi: 10.1093/glycob/cwp084. Epub 2009 Jun 18.

44.

Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations.

Miller MC, Klyosov A, Platt D, Mayo KH.

Carbohydr Res. 2009 Jul 6;344(10):1205-12. doi: 10.1016/j.carres.2009.04.010. Epub 2009 Apr 17.

PMID:
19457477
45.
46.

Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice.

Koenen RR, von Hundelshausen P, Nesmelova IV, Zernecke A, Liehn EA, Sarabi A, Kramp BK, Piccinini AM, Paludan SR, Kowalska MA, Kungl AJ, Hackeng TM, Mayo KH, Weber C.

Nat Med. 2009 Jan;15(1):97-103. doi: 10.1038/nm.1898. Epub 2009 Jan 4.

PMID:
19122657
47.

CXC and CC chemokines form mixed heterodimers: association free energies from molecular dynamics simulations and experimental correlations.

Nesmelova IV, Sham Y, Gao J, Mayo KH.

J Biol Chem. 2008 Aug 29;283(35):24155-66. doi: 10.1074/jbc.M803308200. Epub 2008 Jun 12.

48.

Probing structure-activity relationships in bactericidal peptide betapep-25.

Dings RP, Haseman JR, Mayo KH.

Biochem J. 2008 Aug 15;414(1):143-50. doi: 10.1042/BJ20080506.

PMID:
18489259
49.

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven.

Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH.

Cancer Lett. 2008 Jul 8;265(2):270-80. doi: 10.1016/j.canlet.2008.02.048. Epub 2008 Apr 1.

50.

Galectins: From Theory to Therapy. 23 November 2007, Maastricht, the Netherlands.

Mayo KH.

IDrugs. 2008 Feb;11(2):97-100. No abstract available.

PMID:
18240092

Supplemental Content

Support Center